**CURRICULUM VITAE (Feb 2015)**

**Surname and name: PRENTKI, MARC**

Home address: 126 Wicksteed, Ville-Mont-Royal, PQ H3P2R1, Canada

Telephone (private): (514) 343 4609

Professional address: CRCHUM Tour Viger Local R08-412

 900 Rue St Denis, Montreal H2X 0A9, Canada

Telephone + 1-514-890 8000 ext. 23642

E-mail: marc.prentki@umontreal.ca

[http:// www.mdrc.ca/](http://www.mdrc.ca/)

Place of birth: Paris 14e, France

Citizenships: Canadian, French and Swiss

**Education**

* 10/70-7/75 MSc in Biochemistry, University of Geneva, Switzerland
* 10/76-10/80 PhD in Biochemistry (01/1980) University of Geneva (Prof. B. Jeanrenaud)

**Post-doctoral and Complementary Training**

* 02-80/10-80 Assistant, (PDF) Laboratoire de Recherches Médicales (Dr. B.Jeanrenaud, U of Geneva)
* 11-80/06-84 Maître-Assistant, (PDF) Division de Biochimie Clinique (Dr. A.E. Renold, U of Geneva)
* 07-84/12-85 Research Associate, Diabetes Center (Lab. of Dr. F.M. Matschinsky), U of Pennsylvania, Philadelphia, PA, USA
* 01-86/10-87 Research Assistant Professor, Diabetes Center, U of Pennsylvania, Philadelphia, PA
* 11-87/03-89 Research Assistant Professor, Division de Biochimie Clinique, U of Geneva

**Fellowships and Career Development Awards**

* 06/84 - 06/86 Bourse de chercheur avancé (Post doctoral fellowship) , Swiss National Science Foundation
* 07/86 - 07/87 Career development award, American Diabetes Association
* 08/87 - 06/94 Career development award, Cloëtta Foundation of Switzerland

**Academic Apointments**

* 1989-1994 Maître d'Enseignement et de Recherche (Assistant Professor)

Department of Medicine, University of Geneva

* 1994-1997 Professeur Agrégé (Associate Professor)

Department of Nutrition, University of Montreal

* 1997-present Professeur Titulaire (Full Professor)

Department of Nutrition, University of Montreal

* 1994 present Adjunct Professor

Department of Biochemistry and Molecular Medicine, University of Montreal

* 2005-present Canada Research Chair in Diabetes and Metabolism (Tier 1)
* 2013-present Adjunct Professor

 Department of Medicine, Division of Endocrinology, McGill University

**Other Appointments**

* 2001-2003 Associate Director, McGill and U. Montreal JDRF Diabetes Center for ß-cell replacement
* 2004-present Director, Montreal Diabetes Research Center
* 2010-present Member of the Direction Committee of the Research Center of CHUM
* 2013-present Education Advisory Board of the Danish Diabetes Academy

**Scientific Committees**

* 1994-1997 Juvenile Diabetes Research Foundation
* 1994-1997 Canadian Diabetes Association
* 1996-1997 Cancer Research Society of Montreal
* 1999-2001 Juvenile Diabetes Research Foundation
* 1999-2009 MRC/CIHR, Ad hoc, Nutrition and Metabolism study section
* 2009-2013 CIHR, member, Diabetes Obesity and Lipid disorders study section
* 2001-2010 NIH, Ad hoc, Metabolism/CADO study sections

 **Editorial Boards**

* Associate Editor of Diabetologia (1997-1999)
* Diabetes (1998-2001 and 2001-2004)
* American Journal of Physiology (2001-2003, 2006-2011)
* Journal of diabetes (2009-present)

**Honors and Awards**

* Young Investigator Award, Federation of European Endocrine Societies, Amsterdam, June 1994.
* Canadian Institute of Health Research Scientist (1998-2003)
* Canada Foundation for Innovation Infrastructure grant ($16M; MP, PI; 2004). Creation of the Montreal Diabetes Research Center.
* Arnold Lazarow Memorial lecture (30th). University of Minnesota, Minneapolis, June 2005
* Keynote Lecture of the first Australian Islet Cell Meeting, Sydney Australia Oct 2008.
* Keynote Lecture, Actos Symposium, Takeda Pharmaceuticals, Tokyo, Japan, Oct 2008.
* Ernst-Friedrich Pfeiffer Memorial lecture (11th), Jan 2008, AIDIPT/EASD meeting, Igls Austria.
* Keynote lecture of the11th annual meeting of the early diabetes study group. Takamatsu, Japan. Feb 2008.
* Canada Foundation for Innovation Infrastructure leading edge grant ($15.7M; MP, PI; 2009). Linking basic, clinical and population health research to treat diabetes and metabolic syndrome.
* Plenary lecture, ALFEDIAM meeting, Strasbourg, France, March 2009
* Genome CDN/QC research project ($16.3M; MP, co Director; 2004). The genetics of type 2 diabetes
* Co-authored a landmark paper (Sladek et al Nature 2007) declared paper of the year by the journal Science. The first GWAS study of a complex disease; most quoted paper in diabetes literature three consecutive years.
* Canada Reseach Chair in Diabetes and Metabolism (2005-present).
* Albert Renold Prize of the European Association for the Study of Diabetes for outstanding achievement in Research on the islet of Langerhans. Sept 2011.
* Keynote A. E. Renold lecture of the Swiss association of endocrinology/diabetology. Bern, Switzerland, Dec 2011
* The 30th Lydia J Roberts Memorial Lecture, U Chicago Diabetes Center, Chicago IL, March 2012
* Keynote lecture, The 24th Symposium on Molecular Diabetology, Tokyo, Japan. Dec 2012
* Canada Foundation of Innovation Infrastructure leading edge grant. ($5.8M; MP. PI; 2013). The Montreal Cardiometabolic Biomarker and Drug Discovery Consortium (BIOCMET).
* Keynote lecture, Danish academy of diabetes, Avernae, Denmark, Sept 2013.
* Prize of Excellence of the Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Jan 2015
* Keynote lecture. Alberta-British Columbia Islet workshop. Silver Star, BC, Canada, Feb 2015

**Societies Memberships**

* ALFEDIAM, Francophone Diabetes Association
* American Diabetes Association
* American Society for Biochemistry and Molecular Biology
* Canadian Diabetes Association
* Canadian Society for Nutritional Sciences
* European Association for the Study of Diabetes
* Quebec Diabetes Association
* Endocrine Society

**Industrial Experience**

* 2000-2002 Scientific Advisory Board, H3 Pharma Inc. Montreal
* 2002-2007 Scientific Advisory Board, Innodia Inc. Montreal.
* 2005-2007 Scientific Advisory Board, Chronogen Inc, Montreal
* 2003-2004 Acting Chief Scientific Officer, Innodia Inc. Montreal
* 2011-present Founding member. Betagenex Inc Montreal

**Organization of Scientific Meetings**

1. Boston Ithaca Islet Club meetings (1996, 2002, 2006, 2011)
2. ASBMB 2011 Washington DC meeting. Four symposia on metabolism and diseases (metabolic communication, mitochondrial function and disease, metabolism and cancer, metabolic signaling)
3. Beta-cell workshop group Merck-Frosst Meeting (2005, 2006, 2007, 2008, 2009, 2010)
4. National Atherosclerosis and Cardiometabolic Forum, Toronto 2011

**Major Research Interests**

* Metabolic signal transduction in the pancreatic ß-cell
* Biochemical basis of ß-cell failure in type 2 diabetes
* Glycerolipid metabolism in health and disease
* Cardiometabolic Biomarkers
* Novel drug targets for type 2 diabetes
* Revisiting the dogmas of type 2 diabetes

 **MARC PRENTKI BIBIBLIOGRAPHY (H index: 67)**

#### **Articles in peer-reviewed Journals**

1. **Prentki, M**., Chaponnier, C., Jeanrenaud, B., and Gabbiani, G. Actin microfilaments, cell shape and secretory processes in isolated rat hepatocytes. Effect of phalloidin and cytochalasin D. J. Cell. Biol. **81**: 592-607, 1979.
2. Doi, K., **Prentki, M**., Yip, C., Muller, W. A., Jeanrenaud, B., and Vranic, M. Identical biological effects of pancreatic glucagon and a purified moiety of canine gastric immunoreactive glucagon. J. Clin. Invest. **63**: 525-531, 1979.
3. Crettaz, M., **Prentki, M**., Zaninetti, D., and Jeanrenaud, B. Insulin resistance in soleus muscle from obese Zucker rats. Involvement of several defective sites. Biochem. J. **186**: 525-534, 1980.
4. **Prentki, M**., Crettaz M., and Jeanrenaud, B. A possible complementary role of actin microfilaments and microtubules in triacylglycerol secretion by isolated rat hepatocytes. Biochim. Biophys. Acta **627**: 262-269, 1980.
5. **Prentki, M**., Crettaz, M., and Jeanrenaud, B. Role of microtubules in insulin and glucagon stimulation of amino acid transport in isolated rat hepatocytes. J. Biol. Chem. **256**: 4366-4340, 1981.
6. Assimacopoulos-Jeannet, F., McCormack, J.G., **Prentki, M**., Jeanrenaud, B., and Denton, R.M. Parallel increases in rates of fatty acid synthesis and in pyruvate dehydrogense activity in isolated rat hepatocytes incubated with insulin. Biochim. Biophys. Acta **7l7**: 86-90, 1982.
7. **Prentki, M**., Janjic, D., and Wollheim, C.B. The regulation of extramitochondrial steady-state free calcium concentration by rat insulinoma mitochondria. J. Biol. Chem. **258**: 7597-7602, l983.
8. **Prentki, M**., and Renold, A.E. Neutral amino acid transport in isolated rat pancreatic islets. J. Biol. Chem. **258**: 14239-14244, 1983.
9. **Prentki, M**., Biden, T.J., Janjic, D., Irvine, R.F., Berridge, M.J. and Wollheim, C.B. Rapid mobilization of Ca2+ from rat insulinoma microsomes by inositol-1,4,5-trisphosphate. Nature **309**: 562-564, 1984.
10. **Prentki, M**., Janjic, D., Biden, T.J., Blondel, B. and Wollheim, C.B. Regulation of Ca2+ transport by isolated organelles of a rat insulinoma. Studies with endoplasmic reticulum and secretory granules. J. Biol. Chem. **259**: 10118-10123, 1984.
11. Biden, T.J., **Prentki, M**., Irvine, R.F., Berridge, M.J. and Wollheim, C.B. Inositol l,4,5trisphosphate mobilizes intracellular Ca2+ from permeabilized insulin secreting cells. Biochem. J. **223**: 467-473, 1984.
12. **Prentki, M**., Janjic, D., and Wollheim, C.B. Coordinated regulation of free Ca2+ by isolated organelles from a rat insulinoma. J. Biol. Chem. **259**: 14054-14058, 1984.
13. **Prentki, M**., Wollheim, C.B., and Lew, P.D. Ca2+ homeostasis in permeabilized human neutrophils. Characterization of Ca2+-sequestering pools and the action of inositol l,4,5-trisphosphate. J. Biol. Chem. **259**: 13777-13782, 1984.
14. Gazzano, H., Halban, P., **Prentki, M**., Ballotti, R., Brandenburg, D., Fehlmann, M., and Van Obberghen, E. Identification of functional insulin receptors on membrane from an insulin producing cell line (RINm5F). Biochem. J. **226**: 867-872, 1985.
15. **Prentki, M**., Corkey, B.E., and Matschinsky, F.M. Inositol l,4,5-trisphosphate and the endoplasmic reticulum Ca2+ cycle of a rat insulinoma cell line. J. Biol. Chem. **260**: 9185-9199, 1985.
16. Epstein, P.A., **Prentki, M**., and Attie, M.F. Modulation of intracellular Ca2+ in the parathyroid cell: release of Ca2+ from nonmitochondrial pools by inositol trisphosphate. FEBS Lett. **188**: 141-144, 1985.
17. Falkmer, S., Odselius, R., Blondel, B., **Prentki, M**., and Wollheim, C.B. Energy dispersive X-ray microanalysis of zinc and calcium in organelles of insulin-producing cells of the mouse, rat and a fish. Biomed. Biochim. Acta **44**: 37-43, 1985.
18. **Prentki, M**., Deeney, J.T., Matschinsky, F.M. and Joseph, S.K. Neomycin: a specific drug to study the inositol-phospholipid signalling system? FEBS Lett. **197**: 285-288, 1986.
19. Matschinsky, F.M., Ghosh, A.K., Meglasson, M.D., **Prentki, M**., June V., and Von Allman, D. Metabolic concomitants in pure pancreatic beta cells during glucose-stimulated insulin secretion. J. Biol. Chem. **261**: 14057-14061, 1986.
20. **Prentki, M.**, Glennon, C:., Geschwind, J.-F., Matschinsky, F.M., and Corkey, B.E. Cyclic AMP raises cytosolic Ca2+ and promotes Ca2+ influx in a clonal pancreatic beta cell line (HIT T-15). FEBS Lett.  **220:** 103-107, 1987.
21. Corkey, B.E., Deeney, J.T., Glennon, M.C., Matschinsky, F.M., and **Prentki, M**. Regulation of steady state free Ca2+ levels by the ATP/ADP ratio and orthophosphate in permeabilized RINm5F insulinoma cells. J. Biol. Chem. **263**: 4247-4253, 1988.
22. Corkey, B.E., Tornheim, K., Deeney, J.T., Glennon, M.C., Matschinsky, F.M., Ruderman, N.B. and **Prentki, M**. Linked oscillations of free Ca2+ and the ATP/ADP ratio in permeabilized RINm5F insulinoma cells supplemented with a glycolyzing cell-free muscle extract. J. Biol. Chem. **263**: 4254-4258, 1988.
23. Gilligan, A., **Prentki, M**., Glennon, M.C., and Knowles, B. Epidermal growth factor-induced increases in inositol trisphosphates, inositol tetrakisphosphates and cytosolic Ca2+ in a human hepatocellular carcinoma-derived cell line. FEBS Lett. **233**: 41-46, 1988.
24. **Prentki, M**., Glennon, M.C., Thomas, A.P., Morris, R.L., Matschinsky, F.M., and Corkey, B.E. Cell specific patterns of oscillating free Ca2+ in carbamylcholine-stimulated insulinoma cells. J. Biol. Chem. **263**: 11044-11047, 1988
25. Geschwind, J.F., Hiriart, M., Glennon, M.C., Najafi, H., Corkey, B.E., Matschinsky, F.M., and **Prentki, M.** Selective activation of Ca2+ influx by extracelular ATP in a pancreatic ß-cell line (HIT). Biochim. Biophys. Acta **1012**: 107-115, l989.
26. Corkey, B.E., Glennon, M.C., Chen, K.S., Deeney, J.T., Matschinsky, F.M., and **Prentki,** M**.** A role for malonyl-CoA in glucose-stimulated insulin secretion from clonal pancreatic ß-cells. J. Biol. Chem. **264:** 21608-21612, 1989.
27. Gilligan, A., **Prentki, M.**, and Knowles, B. EGF-receptor down regulation attenuates ligand-induced second messenger formation. Exp. Cell. Res. **187**: 134-142, 1990.
28. Ullrich, S., **Prentki,** M., and Wollheim, C.B. Somatostatin inhibition of Ca2+ induced insulin secretion in permeabilized HIT-T15 cells. Biochem. J. **270**: 273-276, 1990.
29. Longo, E.A.., Tornheim, K., Deeney, J.T., Varnum, B.A., Tillotson,D., **Prentki**, M., and Corkey, B.E. Oscillations in cytosolic free Ca2+, oxygen consumption and insulin secretion in glucose stimulated rat pancreatic islets. J. Biol. Chem.. **266**: 9314-9319, 1991.
30. **Prentki, M**., Vischer, S., Glennon, M.C., Regazzi, R., and Corkey, B.E. Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J. Biol. Chem. **267**: 5802-5810, 1992.
31. Deeney, J.T., Tornheim, K., Korchak, H.M., **Prentki, M.**, and Corkey, B.E. Acyl-CoA esters modulate intracellular Ca2+ handling by permeabilized clonal pancreatic ß-cells. J. Biol. Chem, 267: 19840-19845, 1992.
32. Werlen, G., Belin, D., Conne, B., Roche, E., Lew, D.P., and **Prentki, M**. Intracellular Ca2+ and the regulation of c-*fos* and *zif*268 gene expression in HL-60 myeloid leukemia cells. J.Biol.Chem. 268: 16596-16601, 1993.
33. Brun, T., Roche, E., Kim, K.H., and **Prentki, M**. Glucose regulates acetyl-CoA carboxylase gene expression in a pancreatic ß-cell line(INS1). J.Biol.Chem. **268**: 18905-18911, 1993.
34. Li, S.L., Godson, C., Roche, E., Zhao, S. J., **Prentki, M.** and Schlegel, W. Induction of the c-*fos* gene in pitituiary cells by thyrotrophin releasing hormone and phorbol 12-myristate 13-acetate depends on Ca 2+ influx. J. Mol. Endocrinol. **13**: 303-312, 1994.
35. Frödin M., Sekine, N., Roche, E., **Prentki, M.**, Filloux, C., Wollheim, C.B., and Van Obberghen, E. Glucose, hormonal secretagogues and nerve growth factor activate the mitogen-activated protein(MAP) kinase cascade in the insulin-secreting cell line INS1. J.Biol.Chem. 270: 7882-7889,1995.
36. Brun T., Roche, E., Assimacopoulos-Jeannet, F., Corkey, B.E., Kim, K.H., and **Prentki, M.** Evidence for an anaplerotic/malonylCoA pathway in pancreatic ß-cell nutrient signaling. Diabetes. **45:** 190-198, 1996.
37. Civelek, V.N., Deeney, J.T., Shalosky, N.J., Tornheim, K., Hansford, R.G., **Prentki, M.**, and Corkey, B.E. Regulation of pancreatic ß-cell mitochondrial metabolism: influence of Ca2+, substrate and ADP. Biochem. J. **318:** 615-621, 1996.
38. Brun, T., Assimacopoulos-Jeannet, F., Corkey, B.E., and **Prentki, M.** Long chain fatty acids inhibit acetyl-CoA carboxylase gene expression in the pancreaticß-cell line INS-1. Diabetes **46:** 393-400, 1997.
39. Roche, E., Assimacopoulos-Jeannet, F., Witters, L.A., Perruchoud, B., Yaney, G., Corkey, B., Asfari, M., and **Prentki, M.** Induction by glucose of genes coding for glycolytic enzymes in a pancreatic ß cell line (INS-1). J. Biol. Chem. **272:** 3091-3098, 1997.
40. Assimacopoulos-Jeannet, F., Thumelin, S., Roche, E., Esser, V., McGarry, J.D., and **Prentki, M.** Fatty acids rapidly induce the carnitine palmitoyltransferase I gene in the pancreatic ß-cell line INS-1. 1997 J. Biol. Chem. **272:** 1659-1664, 1997.
41. Schuit, F., De Vos, A., Farfari, S., Moens, K., Pipeleers, D., Brun, T., and **Prentki, M.** Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in ß-cells. J. Biol. Chem. **272:** 18572-18579, 1997.
42. Antinozzi, P.A., Segall, L., **Prentki, M**., McGarry, J.D., and Newgard, C.B. Molecular or pharmacologic perturbation of the link between glucose and lipid metabolism is without effect on glucose-stimulated insulin secretion. A re-evaluation of the long chain acyl-CoA hypothesis. J. Biol. Chem. **273:** 16146-16154, 1998.
43. Roche, E., Farfari, S., Witters, L.A., Assimacopoulos-Jeannet, F., Thumelin, S., Brun, T., Corkey, B., Saha, A.K., and **Prentki, M.** Long term exposure of ß(INS) cells to high glucose concentrations increases anaplerosis, lipogenesis and lipogenic gene expression. Diabetes **47:** 1086-1094, 1998.
44. Susini, S., Roche, E., **Prentki, M.**, and Schlegel, W. Glucose and glucoincretin peptides synergize to induce c-*fos*, *jun*B and *nur*77 gene expression in INS-1 B-cells. FASEB J. **12:** 1173-1182, 1998.
45. Voilley, N., Vicaretti, R., Roduit, R., Bonny, C., Waeber, G., Dyck, J.R.B., Lopaschuk, G.D. and **Prentki, M.** Cloning and expression of rat pancreatic ß-cell malonyl-CoA decarboxylase. Biochem. J. 340: 213-217, 1999.
46. Segall, L., Assimacopoulos-Jeannet, F., Roche, E., Lameloise, N., Thumelin, S., Corkey, P., Corkey, B.E.,and **Prentki, M.** Lipid rather than glucose metabolism is implicated in altered insulin secretion caused by oleate in INS-1 cells. Am. J. Physiol. 277: E521-E528, 1999.
47. Buteau, J., Roduit, R., Susini, S., and **Prentki, M.** Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases PDX-1 DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856-864, 1999.
48. Roche, E., Buteau, J., Aniento, I., Reig, J.A., Soria, B., and **Prentki, M**. Palmitate and oleate induce the immediate-early response genes c-fos and nur77 in the pancreatic ß-cell line INS-1. Diabetes 48: 2007-2014, 1999.
49. Susini, S., van Haasteren, G., Li, S., **Prentki, M.** and Schlegel, W. Essentiality of intron control in the induction of c-fos by glucose and glucoincretin peptides in INS-1 ß-cells. FASEB. J. 14: 128-136, 2000.
50. Hohmeier, H. E., Mulder, H., Chen, G., **Prentki, M.** and Newgard, C. Isolation of INS-1 derived cell lines with robust KATP channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes, 49 : 424-430, 2000
51. Farfari, S., Schulz, V., Corkey, B.E. and **Prentki, M**. Glucose regulated anaplerosis and cataplerosis in pancreatic ß-cells. Possible implication of a pyruvate/citrate shuttle in insulin secretion. Diabetes, 49: 718-726, 2000
52. Deeney, J.T., Gromada, J., Hoy, M., Olsen, H.L., Rhodes, C.J., **Prentki, M**., Berggren, P.O., and Corkey, B.E. Acute stimulation with long chain acyl-CoA enhances exocytosis in insulin secreting cells (HIT T-15 and NMRI ß-cells). J. Biol. Chem. 275: 9363-9368, 2000.
53. Dyck, J.R.B., Berthiaume, L.G., Kantor, P.F., Barr, A.J., Barr, R., Singh, D., Hopkins, T.A., Voilley, N., **Prentki, M**., and Lopaschuk, G.D. Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating fatty acid metabolism. Biochem. J*.* 350: 599-608, 2000.
54. Saha, A.K., Schwarsin, A.J., Roduit, R., Massé, F., Kaushik, V., Tornheim, K., **Prentki, M.**, and Ruderman, N. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase AICAR. J.Biol Chem*.* 275: 34279-24283, 2000.
55. Roduit, R., Morin, J., Massé, F., Segall, L., Roche, E., Newgard, C., Assimacopoulos-Jeannet, F. and **Prentki, M.** Glucose down regulates the expression of the PPARα gene in the pancreatic ß-cell. J. Biol. Chem. 275:35799-35806, 2000.
56. Hardy, S., Langelier, Y. and **Prentki, M.** Oleate activates phosphatidylinositol 3-kinase, promotes proliferation and reduces apoptosis of breast cancer cells whereas palmitate has opposite effect. Cancer Res*.* 60 : 6353-6358, 2000.
57. Dillon, J.S., Yaney, G.C., Zhou, Y. Voilley, N., Bowen, S., Chipkin, S. Bliss, C.R., Schulz, V., Schuit, F., **Prentki, M.,** Waxman, D.J. and Corkey, B.E. Dehydropiandrosterone sulfate and ß-cell function: Enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic ß-cells. Diabetes49: 2012-2020, 2000.
58. Lameloise, N., Muzzin, P., **Prentki, M.,** and Assimacopoulos-Jeannet, F. UCP2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion. Diabetes*,* 50 : 803-809, 2001.
59. Caserta, F., Tschkonia, T., Civilek, V.N., **Prentki, M.,** Brown, N.F., McGarry, J.D., Forse, R.A., Corkey, B.E., Hamilton, J.A. and Kirkland, J.L. Fat depot origin affects fatty acid handling in cultured rat and human preadipocytes. Am. J. Physiol, 280 : E238-247, 2001.
60. Roduit, R., Masiello, P., Wang, S.P., Li, H., Mitchell, G.A., and **Prentki, M.** A role for hormone sensitive lipase in glucose stimulated insulin secretion. A study in hormone sensitive lipase deficient mice. Diabete*s* 50 : 1970-1975, 2001*.*
61. Buteau, J., Foisy, S., Rhodes, C.J. Carpenter, L., Biden, T.J. and **Prentki, M** Protein kinase Czeta activation mediates glucagon-like peptide-1 induced pancreatic ß-cell proliferation.**.** Diabetes*,* 50 :2237-2243, 2001.
62. Masiello, P., Novelli, M., Bombara, M.,, Fierabracci, V., Vittorini, S., **Prentki, M**., Bergamini, E. The antilipolytic agent 3,5-dimethylpyrazole inhibits insulin release in response to both nutrient secretagogues and cyclic adenosine monophosphate agonists in isolated rat islets. Metabolism 51:110-114, 2002.
63. Mason, T.M., Chan, B., El-Baharani, B., Goh, T., Gupta, N., Gamble, J., Shi, Z.Q., **Prentki, M.,**Steiner, G. and Giacca, A. The effect of chronic insulin delivery via the intraperitoneal versus the subcutaneous route on hepatic triglyceride secretion in streptozotocin diabetic rats. Atherosclerosis. 161: 345-52, 2002
64. Alarcon, C., Wicksteed, B., **Prentki, M**., Corkey, B.E. and Rhodes, C.J. Succinate is a prefrential metabolic stimulus-coupling signal for glucose-induced proinsulin biosynthesis translation. Diabetes, 51: 2496-2504, 2002.
65. Park H, Kaushik V.K., Constant S,. **Prentki M**,. Przybytkowski E,. Ruderman N.B,. and Saha AK. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem. 277: 32571-32577, 2002.
66. Buteau, J., Foisy, S., Joly, E. and **Prentki, M.** Glucagon-like-peptide-1 induces pancreatic ß-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 52: 124-132, 2003.
67. Maestre, I., Jordan, J., Calvo, S., Reig, J.-A.é Cena, V., Soria, B., **Prentki, M.** and Roche, E. Mitochondrial dysfunction is involved in apoptosis induced by serum withdrawal and fatty acids in the ß-cell line INS-1. Endocrinology, 144: 335-345, 2003.
68. El-Assaad, W., Buteau, J., Peyot, M.-L., Nolan, C., Roduit, S., Hardy, S., Joly, E., Dbaibo, E., Rosenberg, L., and **Prentki, M.** Saturated fatty acids synergize with elevated glucose to cause pancreatic ß-cell death. Endocrinology 144: 4154-4163, 2003.
69. Hardy S, El-Assaad W, Przybytkowski E, Joly E, **Prentki M,** Langelier Y. Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. J Biol Chem. 278: 31861-70, 2003.
70. Roduit, R., Nolan, C., Alarcon, C., Moore, P., Barbeau, A., Delghingaro-Augusto, V., Przybykowski, E., Morin, J., Massé, F., Massie, B., Ruderman, N., Rhodes, C., Poitout, V., and **Prentki M.** A role for the malonyl-CoA/long chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes 53: 1007-1019, 2004.
71. Buteau, J., El-Assaad, W., Rhodes, C.J., Rosenberg, L., Joly, E. and **Prentki, M**. Glucagon-like peptide-1 prevents ß-cell glucolipotoxicity via protein kinase B/Akt. Diabetologia 47: 806-815, 2004.
72. Hartman, M.G., M.G., Kim, M.-L., Lu, D., Kociba, G.J., Shukri, T., Buteau, J., Wang, X., Frenkel, W.L., Guttridge, D., **Prentki, M.,** Grey, S.T., Ron, D., and Hai, T. ATF3, a new regulator for ß-cell apoptosis: Potential roles in the pathogenesis of type 1 and 2 diabetes.. Mol. Cell. Biol. 24: 5721-5732, 2004.
73. Peyot, M.-L., Nolan, C., Soni, K., Joly, E., Lussier, R., Corkey, B.E., Wang, S.-P., Mitchell, G.A., and **Prentki, M**. Hormone sensitive lipase and lipolysis have a role in lipid signaling for insulin secretion but are non-essential for the incretin action of glucagon-like peptide-1. Diabetes 53: 1733-1742, 2004.
74. Rosenberg, L., Lipsett, M., Yoon, J.-W., **Prentki, M.,** Wang, R., Jun, H.-S.,. Pittenger, G.L., Taylor-Fishwick, D., and Vinik A.I. A pentadecapeptide fragment of islet neogenesis associated protein (Ingap) increases beta-cell mass and reverses diabetes in C57BL/6J Mice. Anal Sug. 240:875-84, 2004..
75. Herrero L, Rubi B, Sebastian D, Serra D, Asins G, Maechler P, **Prentki M**, Hegardt FG. Alteration of the Malonyl-CoA/Carnitine Palmitoyltransferase I Interaction in the ß-Cell Impairs Glucose-Induced Insulin Secretion. Diabetes 54:462-71 (2005).
76. Gremlich S, Nolan C, Roduit R, Burcelin R, Peyot ML, Delghingaro-Augusto V, Desvergne B, Michalik L, **Prentki M**, Wahli W. Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation. Endocrinology 146:375-82 (2005).
77. Park SY, Kim HJ, Wang S, Higashimori T, Dong J, Kim YJ, Cline G, Li H, **Prentki M**, Shulman GI, Mitchell GA, Kim JK. Hormone-Sensitive Lipase Knockout Mice Have Increased Hepatic Insulin Sensitivity and Are Protected from Short-Term Diet-Induced Insulin Resistance in Skeletal Muscle and Heart. Am J Physiol Endocrinol Metab. 289: E30-E39, (2005).
78. Hardy S, St-Onge GG, Joly E, Langelier Y, **Prentki M**. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J Biol Chem. 280:13285-13291, (2005).
79. Pelletier A, Joly E, **Prentki M**, Coderre L. AMPK and p38 MAPK Participate in the Stimulation of Glucose Uptake by Dinitrophenol in Adult Cardiomyocytes. Endocrinology.146:2285-94, (2005).
80. Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, Dina C, Hamid YH, Joly E, Vaillant E, Benmezroua Y, Durand E, Bakaher N, Delannoy V, Vaxillaire M, Cook T, Dallinga-Thie GM, Jansen H, Charles MA, Clement K, Galan P, Hercberg S, Helbecque N, Charpentier G, **Prentki M**, Hansen T, Pedersen O, Urrutia R, Melloul D, Froguel P. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A. 102: 4807-4812, (2005).
81. Assifi MM, Suchankova G, Constant S, **Prentki M**, Saha AK, Ruderman NB. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab. 289:E794-E800, (2005).
82. Joly E, Bendayan M, Roduit R, Saha AK, Ruderman NB, **Prentki M**. Malonyl-CoA decarboxylase is present in the cytosolic, mitochondrial and peroxisomal compartments of rat hepatocytes. FEBS Lett. 579:6581-6586, (2005).
83. Hu L, Deeney JT, Nolan CJ, Peyot ML, Ao A, Richard AM, Luc E, Faergeman NJ, Knudsen J, Guo W, Sorhede-Winzell M, **Prentki M**, Corkey BE. Regulation of lipolytic activity by long-chain acyl-coenzyme A in islets and adipocytes. Am J Physiol Endocrinol Metab. 289:E1085-E1092, (2005).
84. Hu Z, Dai Y, **Prentki M**, Chohnan S, Lane MD. A role for hypothalamic malonyl-CoA in the control of food intake. J Biol Chem. 280:39681-39683, (2005).
85. Kwan EP, Xie L, Sheu L, Nolan CJ, **Prentki M**, Betz A, Brose N, Gaisano HY. Munc13-1 deficiency reduces insulin secretion and causes abnormal glucose tolerance. Diabetes. 55:1421-1429, (2006).
86. Cheyssac C, Dina C, Lepretre F, Vasseur-Delannoy V, Dechaume A, Lobbens S, Balkau B, Ruiz J, Charpentier G, Pattou F, Joly E, **Prentki M**, Hansen T, Pedersen O, Vaxillaire M, Froguel P. EIF4A2 is a positional candidate gene at the 3q27 locus linked to type 2 diabetes in French families. Diabetes. 55:1171-1176, (2006).
87. Spoor DC, Martineau LC, Leduc C, Benhaddou-Andaloussi A, Meddah B, Harris C, Burt A, Fraser MH, Coonishish J, Joly E, Cuerrier A, Bennett SA, Johns T, **Prentki M**, Arnason JT, Haddad PS. Selected plant species from the Cree pharmacopoeia of northern Quebec possess anti-diabetic potential. Can J Physiol Pharmacol. 84:847-58 (2006).
88. Martineau LC, Couture A, Spoor D, Benhaddou-Andaloussi A, Harris C, Meddah B, Leduc C, Burt A, Vuong T, Mai Le P, **Prentki M**, Bennett SA, Arnason JT, Haddad PS. Anti-diabetic properties of the Canadian lowbush blueberry Vaccinium angustifolium Ait. Phytomedicine. 13:612-23, (2006)
89. Nolan CJ, Leahy JL, Delghingaro-Augusto V, Moibi J, Soni K, Peyot ML, Fortier M, Guay C, Lamontagne J, Barbeau A, Przybytkowski E, Joly E, Masiello P, Wang S, Mitchell GA, **Prentki M**. Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia. 49:2120-2130, (2006)
90. Sladek,R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., Balkau, B., Heude, B., Charpentier, G., Hudson, TJ., Montpetit, A., **Prentki, M**., Posner, BI., Balding, DJ., Meyre, D., Polychronakos, C., and Froguel. P. A Genome-wide association study identifies novel susceptibility loci for Type 2 Diabetes mellitus. Nature 445:881-885 (2007)
91. Przybykowski E, Joly, E., Nolan, C.J., Hardy, S., Francoeur, A-M., Langelier, Y. and **Prentki, M**. Upregulation of cellular triacylglycerol/free fatty acid cycling by oleate is associated with long-term serum-free survival of human breast cancer cells. Biochem Cell Biol., 85: 301-310 (2007)
92. Lamontagne J, Masiello P, Marcil M, Delghingaro-Augusto V, Burelle Y, **Prentki M**, Nolan CJ. Circulating lipids are lowered but pancreatic islet lipid metabolism and insulin secretion are unaltered in exercise-trained female rats. Appl Physiol Nutr Metab. 32:241-248 (2007).
93. Guay C., Madiraju S.R., Aumais A, Joly E., **Prentki, M**. A role for ATP-citrate lyase, malic enzyme and pyruvate/citrate cycling in glucose-induced insulin secretion. J Biol Chem. 282: 35657-35665 (2007)
94. Maedler, K., Schulthess FT, Bielman C, Berney T, Bonny C, **Prentki M**, Donath MY, Roduit R.Glucose and leptin induce apoptosis in human ß-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases. FASEB J. 22:1905-13, (2008).
95. Dallaire P, Bellmann K, Laplante M, Gélinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, **Prentki M**, Deshaies Y, Marette A. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism. Diabetes 2008 57:1999-2011, (2008).
96. Rung J., Cauchi, S., Albrechtsen A., Shen L., Rocheleau G., Cavalcanti-Proença C., Bacot F., Balkau B., Belisle A., Borch-Johnsen K., Charpentier G., Dina C., Durand E., Elliott P., Hadjadj S., Riitta-Järvelin M., Laitinen J., Lauritzen T., Marre M., Mazur A., Meyre D., Montpetit A., Pisinger C., Posner B., Poulsen P., Pouta A., **Prentki M.,** Ribel-Madsen R., Ruokonen A., Sandbaek A., Serre D., Tichet J., Vaxillaire M., Wojtaszewski J.F.P., Vaag A., Hansen T., Polychronakos C, Pedersen O., Froguel P., Sladek R. A multi-stage genome-wide association study detects a novel risk locus near IRS1 for type 2 diabetes, insulin resistance, and hyperinsulinemia. Nature Genetics 2009; 41:1110-5.
97. Joly, E., Roduit, R., Peyot, M-L., Habinowski, S.A., Ruderman, N. B., Witters, L.A., **Prentki, M**. Glucose represses peroxisome proliferator-activated receptor gene expression via AMP-activated protein kinase but not via p38 mitogen-activated protein kinase in the pancreatic b-cell. J. Diabetes. 2009; 1: 263-272.
98. Alquier T, Peyot ML, Latour MG, Kebede M, Sorensen CM, Gesta S, Kahn CR, Smith RD, Jetton TL, Metz TO, **Prentki M**, Poitout V. Deletion of GPR40 Impairs Glucose-induced Insulin Secretion in Vivo in Mice Without Affecting Intracellular Fuel Metabolism in Islets. Diabetes. 2009;58:2607-15.
99. Peyot ML, Gray JP, Lamontagne J, Smith PJ, Holz GG, Madiraju SR, **Prentki M**, Heart E. Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells. PLoS One 2009; 4:e6221.
100. Madiraju, P., Pande, S.V., **Prentki, M**., Madiraju, S.R.M. Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epigenetics 2009; 4:399-403..
101. Bendayan M, Londono I, Kemp B, Hardie GD, Ruderman N, **Prentki M**. Association of AMP-activated Protein Kinase Subunits With Glycogen Particles as Revealed In Situ by Immuno-electron Microscopy. J Histochem Cytochem. 2009;57:963-71.
102. Harbilas D, Martineau LC, Harris CS, Adeyiwola-Spoor DC, Saleem A, Lambert J, Caves D, Johns T, **Prentki M**, Cuerrier A, Arnason JT, Bennett SA, Haddad PS. Evaluation of the antidiabetic potential of selected medicinal plant extracts from the Canadian boreal forest used to treat symptoms of diabetes: part II. Can J Physiol Pharmacol. 2009;87:479-92.
103. Lamontagne J, Pepin E, Peyot ML, Joly E, Ruderman NB, Poitout V, Madiraju SR, Nolan CJ, **Prentki M**. Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations. Endocrinology. 2009;150:3465-74.
104. Peyot ML, Guay C, Latour MG, Lamontagne J, Lussier R, Pineda M, Ruderman NB, Haemmerle G, Zechner R, Joly E, Madiraju SR, Poitout V, **Prentki M.** Adipose Triglyceride Lipase Is Implicated in Fuel- and Non-fuel-stimulated Insulin Secretion. J Biol Chem. 2009; 284:16848-59.
105. Delghingaro-Augusto V, Nolan CJ, Gupta D, Jetton TL, Latour MG, Peshavaria M, Madiraju SR, Joly E, Peyot ML, **Prentki M**, Leahy J. Islet beta cell failure in the 60% pancreatectomised obese hyperlipidaemic Zucker fatty rat: severe dysfunction with altered glycerolipid metabolism without steatosis or a falling beta cell mass. Diabetologia. 2009; 52:1122-32.
106. Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, **Prentki M,** Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA.Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia. 2009; 52:723-32.
107. Pepin, E, Guay C, Delghingaro-Augusto V, Joly, E. Madiraju, S.R.M., and **Prentki, M**. Short-chain 3-hydroxyacyl-CoA dehydrogenase is a negative regulator of insulin secretion in response to fuel and non-fuel stimuli in INS832/13 ß-cells. J Diabetes 2010, 2: 157-167.
108. Peyot ML, Pepin E, Lamontagne J, Latour MG, Zarrouki B, Lussier R, Pineda M, Jetton TL, Madiraju SR, Joly E. **Prentki M**. Beta-cell failure in diet-induced obese mice stratified according to body weight gain: secretory dysfunction and altered islet lipid metabolism without steatosis or reduced beta-cell mass. Diabetes 2010: 59:2178-87.
109. Glucolipotoxicity alters lipid partitioning and causes mitochondrial dysfunction, cholesterol, and ceramide deposition and reactive oxygen species production in INS832/13 ß-cells. El-Assaad W, Joly E, Barbeau A, Sladek R, Buteau J, Maestre I, Pepin E, Zhao S, Iglesias J, Roche E, **Prentki M**. Endocrinology 2010: 151:3061-3073.
110. Fontés G, Zarrouki B, Hagman DK, Latour MG, Semache M, Roskens V, Moore PC, **Prentki M**, Rhodes CJ, Jetton TL, Poitout V. Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass. Diabetologia 2010; 53: 2369-2379.
111. Tiano JP, Delghingaro-Augusto V, Le May C, Liu S, Kaw MK, Khuder SS, Latour MG, Bhatt SA, Korach KS, Najjar SM, **Prentki M**, Mauvais-Jarvis F. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β cell failure in rodent models of type 2 diabetes. J Clin Invest 2011; 121:3331-3342.
112. Delghingaro-Augusto V, Décary S, Peyot M-L, Latour MG, Lamontagne J, Paradis-Isler N, Lacharité-Lemieux M, Akakpo H, Birot O, Nolan CJ, **Prentki M**, Bergeron R. Voluntary running exercise prevents the depletion of insulin stores and beta cell failure in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab., 2012; 302:E254-64.
113. Ferdaoussi M, Bergeron V, Zarrouki B, Kolic J, Cantley J, Fielitz J, Olson EN, **Prentki M**, Biden T, Macdonald PE, Poitout VG protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia. 2012; 55:2682-2692.
114. Jacovetti C, Abderrahmani A, Parnaud G, Jonas JC, Peyot ML, Cornu M, Laybutt R, Meugnier E, Rome S, Thorens B, **Prentki M,** Bosco D, Regazzi R. MicroRNAs contribute to compensatory β cell expansion during pregnancy and obesity. J. Clin Invest. 2012; 122:3541-3551.
115. Talbot J, Joly E, Prentki M, Buteau J. β-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic β INS832/13 cells. Mol Cell Endocrinol. 2012;364:65-70
116. Iglesias, J., Barg, S., Vallois, D., Lahiri, S., Roger, C., Yessoufou, A., Pradevand, S., McDonald, A., Bonal, C., Debril, M., Reimann, F., Gribble, F., Metzger, D., Chambon, P., Herrera, P., Rutter, G., **Prentki, M**., Thorens, B. and Wahli, W. Modulation of pancreatic β-cell mass and insulin release by PPARβ/δ in mice. J. Clin Invest. 2012; 122:4105-4117.
117. Lamontagne J, Jalbert-Arsenault E, Pepin E, Peyot ML, Ruderman NB, Nolan CJ, Joly E, Madiraju SR, Poitout V, **Prentki M.** Pioglitazone acutely reduces energy metabolism and insulin secretion in rats. Diabetes 2013; 62:2122-2129.
118. Rancoule C, Attané C, Grès S, Fournel A, Dusaulcy R, Bertrand C, Vinel C, Tréguer K, **Prentki M**, Valet P, Saulnier-Blache JS. Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice. Diabetologia 2013;56:1394-1402.
119. Nesca V, Guay C, Jacovetti C, Menoud V, Peyot ML, Laybutt DR, **Prentki M**, Regazzi R. Identification of particular groups of microRNAs that positively or negatively impact on beta cell function in obese models of type 2 diabetes. Diabetologia 2013;56:2203-2212.
120. Guay C, Joly E, Pepin E, Barbeau A, Hentsch L, Pineda M, Madiraju SR, Brunengraber H, **Prentki M.**

A role for cytosolic isocitrate dehydrogenase as a negative regulator of glucose signaling for insulin secretion in pancreatic ß-cells. PLoS One. 2013; 8:e77097, 1-12

1. Zarrouki B, Benterki I, Fontés G, Peyot ML, Seda O, **Prentki M**, Poitout V. Epidermal Growth Factor Receptor Signaling Promotes Pancreatic β-Cell Proliferation in Response to Nutrient Excess in Rats through mTOR and FOXM1. Diabetes. 2014;63:982-93
2. Zhao S, Mugabo Y, Iglesias J, Xie L, Delghingaro-Augusto V, Lussier R, Peyot M-L, Joly E, Davis MA, Brown JM, Abousalham A, Gaisano H, Madiraju SRM and **Prentki M**. ABHD6 accessible monoacylglycerol is a signal for glucose-stimulated insulin secretion. Cell Metab. 2014;19:993-1007
3. Gauthier MS, Pérusse JR, Lavoie MÈ, Sladek R, Madiraju SR, Ruderman NB, Coulombe B, **Prentki M**, Rabasa-Lhoret R. Increased subcutaneous adipose tissue expression of genes involved in glycerolipid-fatty acid cycling in obese insulin-resistant versus -sensitive individuals. J Clin Endocrinol Metab. 2014; 99:E2518-28
4. Kim-Muller JY, Zhao S, Srivastava S, Mugabo Y, Noh HL, Kim YR, Madiraju SR, Ferrante AW, Skolnik EY, **Prentki M**, Accili D. Metabolic inflexibility impairs insulin secretion and results in MODY-like diabetes in triple FoxO-deficient mice. Cell Metab. 2014;20:593-602
5. Fergusson G, Ethier M, Guévremont M, Chrétien C, Attané C, Joly E, Fioramonti X, **Prentki M**, Poitout V, Alquier T. Defective insulin secretory response to intravenous glucose in C57Bl/6J compared to C57Bl/6N mice. Mol Metab. 2014;3:848-54.

#### **Review Articles**

1. **Prentki, M**., and Wollheim, C.B. Cytosolic free Ca2+ in insulin secreting cells and its regulation by isolated organelles. Experientia 40:1052-1060, 1984.
2. Matschinsky, F.M., Meglasson, M.D., Ghosh, A. Appel, M., Bedoya, F., **Prentki, M.,** Corkey, B.E., Shimizu, T., Berner, D., and Manning, C. Biochemical design features of the pancreatic islet cell glucose-sensor system. Adv. Exp. Med. Biol. 211: 459-469, 1986.
3. **Prentki, M**., and Matschinsky, F.M. Ca2+, cAMP and phospholipid derived messengers in the coupling mechanisms of insulin secretion. Physiol Rev 67: 1185-1248, 1987.
4. Roche, E., and **Prentki, M.** The regulation of immediate-early response genes by Ca2+. Cell Calcium 16: 331-338, 1994.
5. **Prentki, M.** New insights into pancreatic beta-cell metabolic signaling. Eur. J. Endocrinol. 134: 272-286, 1996.
6. **Prentki, M.** and Corkey, B. E. Are the beta-cell signaling molecules, malonyl-CoA and cytosolic long,chain acyl-CoA implicated in multiple tissue effects of obesity and NIDDM? Diabetes 45: 273-283, 1996.
7. **Prentki, M.** Tornheim K. and Corkey, B. E. Signal transduction mechanisms in nutrient induced insulin secretion. Diabetologia, 40: S32-S41, 1997.
8. Corkey, B. E., Deeney, J. T. Yaney, G. Tornheim, K. and **Prentki, M.** The role of long chain acyl-CoA esters in ß-cell signal transduction. J. Nutr., 130 : 299S-304S, 2000.
9. Deeney, J., **Prentki, M.** and Corkey, B. E. Metabolic control of insulin release. Sem. Cell Dev. Biol. 11 :267-275,2000.
10. **Prentki, M.,** Roduit, R., Corkey, B.E., Lameloise, N. and Assimacopoulos-Jeannet, F. Glucotoxicity, lipotoxicity and ß-cell function in diabetes : A role for altered lipid partitioning. Can J. Diabetes Care, 25 : 36-46, 2001.
11. **Prentki, M**., Joly, E., El Assaad, W. and Roduit, R. Malonyl-CoA signaling, lipid partitioning and glucolipotoxicity. Role in ß-cell adaptation and failure in the etiology of diabetes. Diabetes 51: S-405-S413, 2002 .
12. Ruderman NB, Park H, Kaushik VK, Dean D, Constant S, **Prentki M**, Saha AK. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand. 178: 435-42, 2003.
13. Ruderman, N. and **Prentki, M.** AMP-kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Disc, 3: 340-351, 2004.
14. **Prentki M** and Nolan C. Islet ß-cell failure in type 2 diabetes. J. Clin. Invest. 116: 1802-1812, 2006.
15. Nolan CJ, Madiraju SR, Delghingaro-Augusto V, Peyot ML, **Prentki M**. Fatty Acid Signaling in the beta-Cell and Insulin Secretion. Diabetes. 55 Suppl 2:S16-23, 2006.
16. Nolan CJ, **Prentki M**. The islet beta-cell: fuel responsive and vulnerable. Trends Endocrinol Metab. 19:285-91, 2008.
17. **Prentki M**, Madiraju SR. Glycerolipid metabolism and signaling in health and disease. Endocrine Rev. 29:647-76, 2008.
18. Ntimbane T, Comte B, Mailhot G, Berthiaume Y, Poitout V, **Prentki M**, Rabasa-Lhoret R, Levy E. Cystic Fibrosis-Related Diabetes: From CFTR Dysfunction to Oxidative Stress. Clin Biochem Rev. 30:153-77. 2009.
19. Nolan, CJ, Damn, P. and **Prentki M**. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378:169-81, 2011.
20. **Prentki, M.** and Madiraju, SR. Glycerolipid/free fatty acid cycle and islet β-cell function in health, obesity and diabetes. Mol Cell Endocrinol. 2012; 353: 88-100.
21. Nolan CJ, Ruderman NB and **Prentki M.** Intensive insulin for type 2 diabetes: the risk of causing harm. Lancet Endocrinology and Metabolism 1:9-10, 2013.
22. Ruderman NB, Carling D, **Prentki M**, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 2013 Jul 1;123(7):2764-72
23. **Prentki M**, Matschinsky FM, Madiraju SR. Metabolic signaling in fuel-induced insulin secretion. Cell Metab. 18:162-185, 2013.
24. Nolan,CJ, Ruderman, NB, Kahn, SE, Pedersen, O, **Prentki M**. Insulin resistance as a physiological defense against metabolic stress: implication for the management of subsets of type 2 diabetes. Diabetes 64, March 2015

#### **Patents**

* 1. Use of hydroxylated amino acids for treating diabetes. US #20070004623, Jan 4, 2007. Bellini F, Vezeau C, Ribe G, Chapal N, **Prentki M.**
	2. Genetics predictors of risk of type 2 diabetes mellitus. 2007. ROI 07023. Polychronakos C, Sladek R, Posner B, Rocheleau G, Shen L, Rung J, Serre D, Froguel P, **Prentki M**, Dina C.
	3. Screening assays based on MAG and/or ABHD6 for selecting insulin secretion promoting agents. US Patent application filed (12 May 2011). S.R.M. Madiraju, **M. Prentki** and E. Joly.
	4. Insulin Secretion Promoting Agents. Provisional Patent application filed (3 August 2011). S.R.M. Madiraju, **M. Prentki** and E. Joly.
	5. Type 2 Diabetes Biomarkers and uses there of – Provisional Patent application filed. Filing Date: 2013-01-31. E. Paramithiotis, **M. Prentki**, R. RabasaLhoret.
	6. ABHD6 inhibitors to enhance adipose tissues function and browning, Provisional Patent application filed. Filing Date: 28 Feb 2014. S.R.M. Madiraju, S. Zhao, E. Jolyand **M. Prentki**.

***MOST SIGNIFICANT CONTRIBUTIONS DURING CAREER***

***Intracellular Ca2+ homeostasis and signaling.*** The roles of organelles in cytosolic Ca2+ regulation were defined by reconstituting in vitro Ca2+ homeostasis using isolated organelles from ß-cells (JBC 1983 &1984). This work showed that the ER is the principal Ca2+ store and that the mitochondria, plasma membrane and ER act together to restore ambient Ca2+ following its perturbation. Inositol 1,4,5-triphosphate was demonstrated to be a second messenger causing Ca2+ mobilization from the ER (Nature & JBC 1984). Ca2+ signals were shown to be oscillatory in the ß-cell in response to carbamylcholine and the frequency of oscillations varies as a function of the agonist concentration (JBC 1988). Using myeloid leukemia cells, we reported that a transient perturbation of intracellular Ca2+ has long-term effects on gene expression (JBC 1993).

***Metabolic signal transduction in the pancreatic ß-cell.*** Anaplerosis and cataplerosis were shown to play key role in ß-cell activation in response to fuels (JBC 1989, 1992, 1997) via anaplerotic/lipid signaling (Diabetes 1996; TEM 2008). We first proposed that malonyl-CoA and long chain acyl-CoA function as signaling molecules and not only as intermediates or regulators of fat metabolism. In addition we proposed that malonyl-CoA, long chain acyl-CoA and their derivatives participate in the regulation of insulin secretion, insulin action and resistance, and are implicated in the defects of obesity and diabetes (Diabetes 1996), a hypothesis that has been verified by many groups. In collaboration with Dr D. Lane we showed that hypothalamic malonyl-CoA contributes to the control of food intake and body weight (JBC 2005). We also documented that metabolic signal transduction in the ß-cell operates via pyruvate shuttles/cycling (Diabetes 2000), a process providing NADPH and malonyl-CoA as signaling intermediates (JBC 2007). Recently our group provided evidence that lipolysis (Diabetes 2001 & 2004, JBC 2009) and glycerolipid/free fatty acid (GL/FA) cycling (Diabetologia 2006) do not act solely in cells for energy storage and mobilization purposes, but are involved in a variety of biological processes including insulin secretion, cell growth and fuel excess detoxification (Endocr Rev. 2008). Finally, by studying acetyl-CoA carboxylase gene expression, we demonstrated that glucose can directly regulates gene expression in mammalian cells (JBC 1993). These signal transduction systems and pathways that our lab contributed to identify (anaplerosis, cataplerosis, malonyl-CoA/ fatty acyl-CoA network, pyruvate shuttle/cycling, (GL/FA) cycling, direct regulation of gene expression by glucose) had much implications for nutrient sensing at large in health and disease.

***The glucolipotoxicity concept and ß-cell failure in type 2 diabetes.*** We developed the concept of glucolipotoxicity that has implication for the etiology of adipogenic diabetes. In this model, elevated fatty acids and glucose synergize to cause reduced insulin secretion and ß-cell apoptosis (Diabetes 1996; Endocrinology 2003, 2010). We have recently developed the concept that (GL/FA) cycling acts also as a fuel ‘detoxification’ process and produces signals for insulin secretion, thus allowing ß-cell compensation for insulin resistance (Diabetologia 2006; J Clin Invest 2006; Endocr Rev.2008).

***Glucagon-like peptide and ß-cell growth.*** We first showed that GLP-1acts as a ß-cell growth factor (Diabetologia 1999) via transactivation of the EGF receptor, PI-3 kinase activation, PKCζ translocation and the induction of the ß-cell specific transcription factor PDX-1, together with immediate early response genes (FASEB J 1998; Diabetes 2001 & 2003). In addition GLP-1 was found to protect human ß-cells from glucolipotoxicity via PKB (Diabetologia 2004) and to potentiate GSIS without accelerating glucose and energy metabolism in rodent islets (PloS One 2009).

***Genetics of type 2 diabetes.*** MP co-directed a large-scale project on the genetics of T2DM using a multi stage genome-wide association study (GWS). This was the first GWS for any disease, and thus provided proof of concept for this approach. The study identified four novel T2DM risk loci, including a non-synonymous polymorphism in the Zinc transporter (ZnT8) of the insulin secretory granule (Nature 2007). Completion of the study using additional cohorts identified a risk locus near IRS1 for T2D, insulin resistance and hyperinsulinemia (Nature Genetics 2009).

**Invited Speaker, Chairmanship and Advisory Boards (2005-2014)**

1. Symposium on obesity and diabetes, Al Jouf University, Aljouf-Sakara, K Saudi Arabia, April 2014
2. Hamad Medical Corporation Hospital, Doha, Quatar, Jan 2014.
3. Quatar Biomedical Research Institute Symposium on the System biology of diabetes. Doha, Quatar, Jan 2014.
4. Symposium of the French Diabetes Association. Diabetes and the ß-cell. Paris, France, Dec 2013.
5. Danish academy of diabetes, Keynote lecture, Avernae, Denmark, Sept 2013.
6. American Diabetes Association meeting, Symposium on lipotoxicity, Chicago, USA, June 2013.
7. Peking University Diabetes Center, Beijing, China, June 2013.
8. Jiatong Rui-Jin Hospital, Grand rounds, Shanghai, China, June 2013.
9. Jiatong University, Department of Endocrinology and Diabetes, Shanghai, China, June 2013.
10. University of traditional Chinese medicine diabetes center, Beijing, China May 2013.
11. Beta cell workshop, Kyoto, Japan, April 2013.
12. Graduate student program special lecture, University of Utsunomiya , Utsunomiya, Japan, April 2013.
13. Collossus-CMDO meeting on cardiometabolic disorders, Quebec city, Canada, Feb 2013.
14. McGill University, Goodman Cancer Research Centre, Montreal, QC, Canada. Feb 2013
15. Tokyo University Diabetes Center, Tokyo, Japan. Dec 2012
16. Plenary Lecture, The 24th Symposium on Molecular Diabetology, Tokyo, Japan. Dec 2012
17. Diabète Québec annual meeting, Quebec city, QC, Canada, Nov 2012
18. Merck, Rahway NJ, Sept 2012
19. Summer School on Metabolism, U Odensee, Denmark, Sept 2012.
20. Jan Hoek Symposium on mitochondrial metabolism, Thomas Jefferson U, Philadelphia, PA, June 2012
21. Dasman-McGill Symposium, Dasman Diabetes Center, Koweit city, Koweit, May 2012
22. University of Pennsylvania Diabetes Center, Philadelphia PA, May 2012
23. The 30th Lydia J Roberts Memorial Lecture, U Chicago Diabetes Center, Chicago IL, March 2012
24. Lady Davis Institute, McGill University, Montreal, QC, Canada. March 2012
25. Rachmiel Levine Diabetes Symposium, City of Hope, CA. Feb 2012
26. Tianjin Novo Nordisk Diabetes Meeting, Quingdao, China, Feb 2012
27. Pfizer, Boston MA, Jan 2012
28. Albert Renold lecture of the swiss society of Endocrinology and diabetology, Bern, Switzerland, Dec 2011
29. Beta Cell workshop on beta cell signaling and regeneration, Helisngor, Denmark, Oct 2011
30. Albert Renold lecture (5th), EASD Meeting, Lisbon, Portugal, Sept 2011
31. Keystone Meeting on Lipotoxicity and complex diseases, Killarney Ireland, May 2011
32. Symposium on metabolic signaling, ASBMB 2011 Washington DC, April 2011
33. Chairman, symposium on metabolism and cancer, ASBMB 2011 Washington DC, April 2011.
34. Division of Endocrinology and Metabolism, University of Pittsburgh, PA, March 2011
35. Dept of Anatomy and Cell Biology, McGill University, Canada, February 2011
36. Andràs Spät Symposium on Ca2+ and cell signaling, Budapest, Hungary, Nov 2010
37. J A de Sève Chair Symposium on Nutrition, Montreal, Canada, Nov 2010
38. Chairman, Symposium on metabolic syndrome, Intl congress of Pathology, Montreal, Canada, Sept 2010
39. Symposium on metabolic syndrome, Intl congress of Pathology, Montreal, Canada, Sept 2010
40. Boston University Diabetes Ctr, Boston MA, Sept 2010
41. Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland, Sept 2010
42. Claes Wollheim Symposium on beta cell and diabetes, Geneva, Switzerland, May 2010
43. Keystone Symposium on Islet Biology, Whistler, Canada, April 2010
44. Keystone Symposium on beta cell growth/survival control, Chairman, Whistler, Canada, April 2010
45. Summer School on Metabolism, U Odensee, Denmark, Sept 2009.
46. Physiological Society meeting, Symposium on insulin secretion, Dublin, Ireland, July 2009
47. ACVIM meeting, fuel signaling symposium, Montreal, Canada, June 2009
48. Diabetes and obesity symposium, ACVIM meeting, Montreal, Canada, June 2009
49. ALFEDIAM meeting, Chairman, Symposium on insulin secretion, Strasbourg, France, March 2009
50. Plenary lecture, ALFEDIAM meeting, Strasbourg, France, March 2009
51. Keynote Lecture of the first Australian Islet Cell Meeting, Sydney Australia Oct 2008.
52. Medical Round, Canberra Australia, Oct 2008
53. Baker Institute, Melbourne, Australia, Oct 2008.
54. Keynote Lecture, Actos Symposium, Takeda Pharmaceuticals, Tokyo, Japan, Oct 2008.
55. Strategic Meeting on diabetes and ß-cell research at Merck. Merck, Rahway, NJ Dec 2008.
56. Summer School on Metabolism, U Odensee, Denemark, Sept 2008.
57. 11th Ernst-Friedrich Pfeiffer Memorial lecture. Beta cell failure and methods to reverse it. Jan 2008, AIDIPT/EASD meeting, Igls Austria.
58. Keynote lecture of the11th annual meeting of the early diabetes study group. Takamatsu, Japan. Feb 2008.
59. Symposium on ß-cell metabolic signaling, Chiarman, KEYSTONE meeting on islet ß-cell Biology. Snowbird, Utah. April, 2008.
60. Symposium on pancreatic ß-cell function. Novel insights into pancreatic ß-cell metabolic signaling. Annual Meeting of the Japanese Diabetes Association. Tokyo, Japan, May 2008.
61. 3nd Canadian Beta Cell Working Group, Toronto, ON. Nov 2007.
62. Summer School on Metabolism, Lecture & Course, U Odensee, Denmark, Sept 2007
63. Chronogen Inc Advisory board, Montreal, Canada, June 2007
64. Bristol Myers Squibb, Lecture & Advisory Board, NJ, USA, May 2007
65. Chinese diabetes association meeting, U Beijing, China, May 2007
66. Merck-Frosst, Strategic meeting on diabetes, May 2007
67. Case Western University, Dept Nutrition, March 2007
68. ADA symposium, Translating Islet Biology into Diabetes Therapy, Stone Mountain, GA, March 2007.
69. International Diabetes Federation, Cape Town, South Africa, Dec 2007
70. 2nd Canadian Beta Cell Working Group, Toronto, ON. Nov 2006.
71. Rui-Jin Symposium on diabetes, Shanghai, China, Oct 2006
72. Summer School on Metabolism/diabetes, Lecture & Course, U Odensee, Denmark, Sept 2006
73. Graz University, Dept Biochemistry, Austria, Sept 2006
74. FASEB Symposium on AMP-Kinase, Lecture & Chairman, Snowmass, CO, Aug 2006
75. University of Barcelona, symposium on ß-cell failure, May 2006
76. Naomie Berrie diabetes Ctr at Columbia, Site visit and external advisor. NYC, NY, May 2006
77. Servier symposium on fuel signaling, Cap Ferrat, France, March 2006
78. Keystone Symposium “Towards Understanding Islet Biology”. Lecture & Chairman. Taos, NM, Feb 2006.
79. 1st Canadian Beta Cell Working Group, Lecture & Chairman, Toronto, ON. Nov 2005.
80. D-Cure meeting on diabetes, Jerusalem, Israel, Sept 2005
81. EASD meeting, symposium on the fat overflow hypothesis, Athens, Greece, Sept 2005
82. JDRF/EASD meeting on ß-cell replacement, Oxford, UK, Aug 2005
83. Novartis Institute, External Advisory Board., Cambridge, MA, USA, July 2005
84. ADA meeting, Symposium on fatty acids and diabetes, San Diego, June 2005
85. 30th Arnold Lazarow Memorial lecture. University of Minnesota, Minneapolis, June 2005
86. Innodia Inc Montreal, Scientific Advisory Board, Feb 2005.